Manufacturers report positive results for ganaxolone in children and young adults with CDKL5 deficiency disorder
In a phase III study, this positive allosteric modulator of GABAA receptors reduced seizure burden by 32.2% vs 4% for placebo in patients with this condition who had on average tried 7 different seizures medications prior to the study.
Source:
Biospace Inc.